Results 31 to 40 of about 2,862,567 (165)

Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting

, 2020
To evaluate the durability of three integrase strand transfer inhibitors (INSTIs) and two NRTIs in ART-naive ...
Antinori Andrea, Lo Caputo, Sergio, Marchetti GC, Cingolani A, Gianotti N, Cinque P, Iardino R, Rusconi S, Bandera A, Quiros Roldan E, Girardi E, Maggiolo F, Galli M, Costantini, Andrea, De Luca A, Rezza G, Andreoni M, Di Perri G, Puoti M, Madeddu G, Gianotti, Nicola, von Schloesser F, Sarmati L, Marchetti, Giulia, Guaraldi G, Castelli F, Perno CF, Borderi M, Santoro MM, Rossotti R, Mazzotta, Valentina, Cauda R, Pinnetti C, Cozzi-Lepri, Alessandro, Capobianchi MR, Ceccherini-Silberstein F, Marchetti G, Castagna, Antonella, Lazzarin A, Saracino A, Capetti A, Antinori A, Nozza S, Di Biagio, Antonio, Cozzi-Lepri A, Viale P, Gori A, Castagna A, d'Arminio Monforte, Antonella, Rusconi, Stefano, Di Biagio A, Ippolito G, d'Arminio Monforte A, Mazzarello, Giovanni, Calcagno A, Cicalini S, Lapadula G, Lo Caputo S, Monno L, Bonora S, Balotta C, Mussini C, Lichtner M   +62 more
core   +1 more source

Potential drug–drug interactions in the era of integrase strand transfer inhibitors: a cross-sectional single-center study in Japan

Journal of Pharmaceutical Health Care and Sciences, 2021
Background Potential drug–drug interactions (PDDIs) commonly occur because of aging and comorbidities in people living with human immunodeficiency virus (HIV; PLWH).
Yusuke Kunimoto, Ryosuke Matamura, Hiroshi Ikeda, Satoshi Fujii, Tomoko Kimyo, Manabu Kitagawa, Hiromasa Nakata, Masayoshi Kobune, Atsushi Miyamoto, Masahide Fukudo   +9 more
doaj   +1 more source

Discovery of Novel Integrase Inhibitors Acting outside the Active Site Through High-Throughput Screening

Molecules, 2019
Currently, an increasing number of drugs are becoming available to clinics for the treatment of HIV infection. Even if this targeted therapy is highly effective at suppressing viral replication, caregivers are facing growing therapeutic failures in ...
Cindy Aknin, Elena A. Smith, Christophe Marchand, Marie-Line Andreola, Yves Pommier, Mathieu Metifiot   +5 more
doaj   +1 more source

Antiretroviral Levels in the Cerebrospinal Fluid: The Effect of Inflammation and Genetic Variants

Diagnostics, 2023
Neurocognitive impairments are common in people living with HIV. Some conditions, such as chronic inflammation, astrocyte infection and an impaired blood–brain barrier (BBBi), along with host genetic variants in transporter genes, may affect ...
Jessica Cusato, Valeria Avataneo, Miriam Antonucci, Mattia Trunfio, Letizia Marinaro, Alice Palermiti, Alessandra Manca, Giovanni Di Perri, Jacopo Mula, Stefano Bonora, Antonio D’Avolio, Andrea Calcagno   +11 more
doaj   +1 more source

Primary resistance to integrase strand-transfer inhibitors in Europe [PDF]

, 2015
Objectives: The objective of this study was to define the natural genotypic variation of the HIV-1 integrase gene across Europe for epidemiological surveillance of integrase strand-transfer inhibitor (InSTI) resistance.
Pou, Christian, Hofstra, L. M., Kostrikis, L.G. (Leondios), Poljak, M. (Mario), Vandercam, Bernard, Pou, C., Wensing, A.M.J., van Kessel, A, Staneková, D, Puchhammer-Stoeckl, E., Hoepelman, A.I.M., Wensing, A M J, Boucher, CAB, Wensing, A.M.J. (Annemarie), Somogyi, S, van Ham, P.M. (Petra), Hoepelman, A I, Struck, D. (Daniel), Noguera-Julian, M., Bakken Kran, A. M., Paraskevis, D. (Dimitrios), Hoepelman, A. I., Stanojevic, M, Linka, M. (Marek), Wensing, A. M. J., van Ham, P M, Stanekova, D. (Danica), Hofstra, L M, Lepej, S. Zidovec, Paredes, R. (Roger), Otelea, D, Poljak, M., Liitsola, K, Van Laethem, K., Zidovec Lepej, S. (Snjezana), Paredes, R., Liitsola, K. (Kirsi), Noguera-Julian, Marc, Wensing, AMJ, Linka, M., Puchhammer-Stöckl, E, Santos, José R., Zidovec Lepej, S, Santos, J. R., Paredes, R, Hoepelman, AI, Wensing, A.MJ., Otelea, D. (Dan), SPREAD Programme, Casadella, M., Stanojevic, M., Yombi, Jean Cyr, Linka, M, Hofstra, L.M. (Marije), Boucher, C. A. B., Casadellà, M, Santos, J R, Pedersen, Court, Paraskevis, D., Paraskevis, D, Clotet, Bonaventura, Pou, C, Otelea, D., Zidovec Lepej, S., Boucher, C.A.B., Kran, AMB, Lepej, SZ, Paredes, Roger, Santos, J.R., Van Laethem, K. (Kristel), Metcalf, G.A. (Ginger A.), Goubau, Patrick, Kostrikis, L. G., Verhofstede, Chris, Alexiev, I., Clotet, B., Boucher, C.A.B. (Charles), Poljak, M, Clotet, B, Puchhammer-Stöckl, E. (Elisabeth), Bakken Kran, A.M., Garcia, F., Nielsen, C., Boucher, C A B, Van Laethem, Kristel, Garcia, Federico, Somogyi, S., SPREAD programma, on behalf of the, Van Ham, P.M., Kran, A. M. Bakken, Hofstra, LM, Van Laethem, K, SPREAD programme investigators, Boucher, Charles, Vandekerckhove, Linos, Casadellà, Maria, Alexiev, I, Alexiev, I. (Ivailo), Stanekova, D., Liitsola, K., Puchhammer-Stöckl, E., van Ham, PM, Bakken Kran, AM, van Ham, P. M., Garcia, F, van Kessel, A., Vekemans, Marie-Christiane, Stanojevic, M. (Maja), Nielsen, C, Hoepelman, A.I., Kostrikis, L G, Struck, D, Noguera-Julian, M, Santos, JR, Bakken Kran, A M, Struck, D., Kostrikis, L.G., Kostrikis, LG, Boucher, C.AB., Hofstra, L.M., Pou, C,, van, Ham PM, van, Kessel A   +122 more
core   +4 more sources

Multiple choices for HIV therapy with integrase strand transfer inhibitors

Retrovirology, 2012
Two integrases inhibitors, raltegravir and elvitegravir, have now been approved by regulatory agencies for use in the treatment of HIV-infected patients; and the approval of a third such drug, dolutegravir, is expected during 2013 on the basis of several
Raffi Francois, Wainberg Mark A
doaj   +1 more source

Study on suitable analysis method for HIV-1 non-catalytic integrase inhibitor

Virology Journal, 2021
Background Integrase (IN) is an essential protein for HIV replication that catalyzes insertion of the reverse-transcribed viral genome into the host chromosome during the early steps of viral infection. Highly active anti-retroviral therapy is a HIV/AIDS
Ki Hoon Park, Minjee Kim, Seoung Eun Bae, Hee Jung Lee, Kyung-Chang Kim, Byeong Sun Choi, Young Bong Kim   +6 more
doaj   +1 more source

Pharmacophore-Based Design of HIV-1 Integrase Strand-Transfer Inhibitors

, 2016
Using a training set of diketo-like acid HIV-1 integrase (IN) strand-transfer inhibitors, a 3D pharmacophore model was derived having quantitative predictive ability in terms of activity.
Alba Chimirri (76729), Stefania Ferro (76724), Angela Rao (2665219), Anna-Maria Monforte (2665222), Zeger Debyser (20227), Maria Zappalà (2452153), Laura De Luca (76726), Maria Letizia Barreca (76727), Myriam Witvrouw (273990)   +8 more
core   +1 more source

Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens. [PDF]

PLoS ONE, 2012
Human immunodeficiency virus type 2 (HIV-2) is intrinsically resistant to non-nucleoside reverse transcriptase inhibitors and exhibits reduced susceptibility to several of the protease inhibitors used for antiretroviral therapy of HIV-1. Thus, there is a
Robert A Smith, Dana N Raugi, Charlotte Pan, Matthew Coyne, Alexandra Hernandez, Brad Church, Kara Parker, James I Mullins, Papa Salif Sow, Geoffrey S Gottlieb, University of Washington-Dakar HIV-2 Study Group   +10 more
doaj   +1 more source

Pharmacophore-Based Design of HIV-1 Integrase Strand-Transfer Inhibitors

, 2005
Using a training set of diketo-like acid HIV-1 integrase (IN) strand-transfer inhibitors, a 3D pharmacophore model was derived having quantitative predictive ability in terms of activity.
MONFORTE, Anna Maria, Ferro S., M. WITVROUW, DE LUCA, Laura, ZAPPALA', Maria, Z. DEBYSER, Debyser Z., Chimirri A., Monforte A. M., BARRECA, MARIA LETIZIA, Witvrouw M., FERRO, Stefania, CHIMIRRI, Alba, Rao A., De Luca L., Zappalà M., RAO, Angela   +16 more
core   +1 more source